Skip to content

FDA OKs Teva’s generic pemetrexed for lung cancer

August 24, 2020

The FDA approves Teva Pharmaceutical Industries (TEVA -2.6%) unit Actavis’ generic pemetrexed for the treatment of locally advanced or metastatic non-squamous non-small cell lung cancer (NSCLC) that has not progressed after four cycles of first-line platinum-based chemo.

https://seekingalpha.com/news/3608341-fda-oks-tevas-generic-pemetrexed-for-lung-cancer

From → Uncategorized

Leave a Comment

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out /  Change )

Google photo

You are commenting using your Google account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s

%d bloggers like this: